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LITERATURE SURVEY
Introduction
Immunological tolerance is the phenomenon whereby antigen interacts
with the lymphoid system to impair its capacity to later respond to that
antigen. The ability of an individual's immune system to distinguish its
own tissues from "non-self" was recognized as early as 1900 by Ehrlich,
who noted that an organism is capable of mounting an immune response to
nearly any substance other than its own tissues. Cross immunization
between different strains of inbred mice (congeneic) produces immune
responses directed at the alloantigens the recipient lacks, but not those
it possesses.
The history of immunological tolerance has been briefly reviewed by
Nossal (1). The apparent unresponsiveness to some antigens was coined
'tolerance' in 1945 by R.D. Owen (1). Dizygotic twin cattle, sharing a
common placenta, showed the establishment of erythrocyte precursors of
each of the twins in the other fetus. Owen noted that this conferred a
tolerant state toward the shared antigens that lasted throughout the
lifetime of their new host.
In 1953, Billingham (2) confirmed this observed state of tolerance
using living cells as a source of alloantigens. Billingham injected
suspensions of spleen, kidney and testes of A strain mice into 15 and 16
day fetal CBA mice. Eight weeks following birth the mice received skin
grafts from A strain donors. Three of five mice failed to reject the
graft. Further, these mice did not reject second and third allografts
received 50 and 90 days after the first. Intraperitoneal adoptive
transfer of immunocytes from CBA animals that had rejected A strain skin
grafts resulted in graft rejection. The most substantial contribution of
this work came when the tolerant response was shown to be antigen
specific, since CBA mice rendered tolerant to A strain tissue rejected
skin grafts from AU mice
In 1962, Dresser (3) reported that minute quantities of
aggregate-free bovine gamma globulin (BGG), injected intravenously, could
induce tolerance in adult mice. Serum obtained from adult mice immunized
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with BGG in Freund's adjuvant failed to precipitate I labeled BGG.
He called the nonreactive state "Immune Paralysis" and found that the
condition could be maintained by continued injections of BGG while the
animal was still paralyzed. This discovery was significant because it
raised the possibility that even mature immunocytes could receive
negative signals from antigen. Previously, tolerance had been thought to
exist only in neonates or fetal animals undergoing "self" definition.
The existence of antigen specific suppressor T lymphocytes following
antigen administration was demonstrated by Gershon and Kondo in 1970 (4,
5). Groups of adult mice were thymectomized , lethally irradiated and
reconstituted with syngeneic bone marrow. One group was then injected
with syngeneic thymus cells, the other was not. In an attempt to induce
tolerance, both groups were then subjected to repeated injections of high
concentrations of sheep red blood cells (SRBC). After several weeks of
this regimen, both groups received thymus cells as a source of helper
cells, and were challenged with SRBC. Measurement of the anti-SRBC
plaque forming response revealed that the group which had received the
initial thymic reconstitution did not produce anti-SRBC antibody. From
this and similar experiments, Gershon argued that the presence of thymus
cells during the course of injections prevented or suppressed the
generation of anti-SRBC responses. Although this interpretation met with
almost universal resistance, T suppressor cells have now been identified
in a wide array of immunological systems. The preceding experiments
proved the existence of tolerance as an immune condition, and allowed
development of contemporary model T suppressor systems. Although some
confusion exists, T suppressor systems are thought to be inducible by
antigen and specific for the inducing antigen.
Two general cellular mechanisms appear to account for the induction
of tolerance, clonal deletion and immunosuppression. Clonal deletion
involves elimination or inactivation of reactive T or B cell clones. In
contrast, the immunosuppressive state is characterized by the presence of
potentially reactive clones whose function is blocked by suppressor
cells. Immunological tolerance cannot be explained simplistically.
Immune networks represent large populations of interacting cells of
several subtypes. Thus any cell capable of promoting an immune response
is also capable of blocking that response. Macrophages (6-9) and B cells
(10) in addition to T cells have been reported to be immunosuppressive.
The cell type responsible for tolerance appears to be dependent on the
eliciting antigen, or mitogen. Given the diversity of antigens, and
responses to those antigens, the theory of clonal deletion has been
weakened. Nossal (2) has asserted that since the affinity of antibody
varies greatly, and the amount of crossreactivities is relatively large,
clonal deletion cannot be correct since there would be a real possibility
of deleting the entire immune repertoire. Given these considerations the
ensuing review will consider only T cell-mediated immunosuppression.
Common Features of J_ Suppressor systems .
Agreement on a comprehensive suppressor T cell scheme that
intergrates all available data has been hampered by the fact that most
laboratories have analyzed the suppressive response in different model
systems. Furthermore, T suppressor cells can modulate a variety of
immune responses that involve both cellular and humoral immunity.
Suppressor T cell populations have been described with activities that
range from "antigen specific and genetically (IJ) restricted to
non-antigen-specific and non-genetically restricted with all permutations
between the two extremes" (11). In an attempt to avoid any further
confusion, the term restriction used in this paper will refer to genetic
control. Specificity will refer to selective reactivity of the immune
response to antigen.
Several features are common to both specific and nonspecific
suppressor T cell systems. First, several cell subsets interact
sequentially to produce the suppressive effect. In nonspecific systems
such as the Soluble Immune Response Suppressor system (SIRS), this
involves at least one set of T cells interacting with macrophages (11).
In general, interaction between 2 and sometimes 3 T cell subsets with
antigen presenting cells is required for the induction of
immunosuppression (12). Both specific and nonspecific Ts cells appear to
exert their effects through soluble mediators known as suppressor factors
(TsF). Released from the Ts cell, these factors are intimately involved
in the aforementioned sequential circuits. These factors provide for
induction, activation, and/or effector cell signals required for
communication between various T cell populations. TsF perform two
functions important in suppressor regulatory circuits; reactions occur at
distances eliminating the need for cell-cell contact, and Ts and TsF are
effective in low concentrations.
Antigen Nonspecific Immunosuppression .
Antigen nonspecific suppressor T lymphocytes have been described in
vitro in human (13) and a variety of other animal systems (14).
Nonspecific suppressor cell pathways can be induced with lectins such as
Concanavalin A (Con-A) or interferons (15) and have been detected in
vivo in animals bearing virally induced tumors (16). In addition,
macrophages (7-9) and B lymphocytes (10, 16) are suggested mediators of
nonspecific suppression.
The mechanism of action of Con-A-activated suppressor T cells has
been extensively studied as a model in murine systems. These suppressor
cells are Ly 2 T cells which inhibit a variety of immune responses
including IgM and IgG plaque-forming cell responses, cytotoxic T cell
response, and proliferative responses to alloantigens and mitogens by the
release of a mediator called soluble immune response suppressor (SIRS)
(14). SIRS lacks both restriction and specificity, is not absorbed by
antigen, anti-mouse immunoglobulin, mouse immunoglobulin, anti H-2 sera,
or anti-la sera. However, SIRS is absorbed by spleen cells or isolated
macrophages, but not kidney cells (11, 17).
In early studies on the induction of Con-A stimulated suppressor
cells, nylon wool nonadherent T lymphocytes were found to be directly
stimulated by mitogenic doses of the lectin. Depletion of macrophages by
adherence in the early induction events did not alter the suppressive
effects of supernatants obtained from such cultures. However, deletion
of macrophages in mixed lymphocyte tissue cultures to which SIRS had been
added abolished suppression (11). Furthermore, SIRS must be added to
these cultures within 6 hours of initiation, for a period of 2 hours, to
suppress the antibody response.
SIRS has been biochemically characterized by Tadakuma (17). SIRS was
shown non-dialyzable, and the suppressive effect was stable after
treatment at 56 C for 30 minutes, but destroyed by temperature of 70
C for 30 minutes. Enzymatic treatment with DNAase and RNAase did
not effect suppression while degradation with trypsin and chymotrypsin
did. Gel filtration on Sephadex G-100 columns resulted in elution of
SIRS activity in fractions corresponding to a molecular weight range
between 48,000 and 67,000 Daltons. Density centrifugation in CsCl
gradients led the author to believe that SIRS is glycoprotein in nature.
Polyacrylamide gel electrophoresis (PAGE) did not allow SIRS to be
distinguished from migration inhibitory factor (MIF).
Macrophages are directly involved in the processing of SIRS to
produce macrophage suppressor factor (M0SF). Tadakuma (18) added
supernatants of Con A-treated splenocytes to cortisone-resistant
thymocytes, adherent peritoneal exudate cells and adherent spleen cells,
and cell suspensions depleted of T cells by treatment with anti Thy 1.1
antibody and complement. Following 2 hours incubation, supernatants were
removed and tested for their ability to disrupt antibody responses to
sheep red blood cells in vitro . Supernatants obtained from
adherent cell populations treated with SIRS consistently showed the
ability to suppress the in vitro plaque forming response to SRBC,
while populations of T and B cells did not alter plaque formation.
Aune and Pierce (19) have produced a continual source of SIRS by
stimulating spleen cells with 2 ug/ml Con A and then fusing with the
hypoxanthine/guanine phosphoribosyl transferase deficient AKR thymoma
BW5147 using polyethylene glycol. The resultant clones, selected in
medium containing hypoxanthine, aminopterin and thymidine (HAT),
constitutively produced a glycoprotein with biological and physical
characteristics similar to those previously described. SIRS produced in
this manner was shown to be effective in suppressing antibody formation
as demonstrated by hemolytic plaque assay after exposure to macrophages
and the macrophage-like cell line RAW 246.7. The suppressive activity of
this M0SF was shown to be present in fractions corresponding to a
molecular weight of 55,000 Daltons following Sephacryl G-200 gel
filtration. Biological activity was lost after treatment with
chymotrypsin, at pH 3, and after exposure to sulfhydryl reagents
2-mercaptoethanol, dithiothreitol, sodium borohydride, taurine, and
ethanolamine. Further studies (20) demonstrated the mechanism of
macrophage processing. Hybridoma-derived SIRS was reacted with picomolar
quantities of hydrogen peroxide for various time periods and then tested
by adding the product to anti-SRBC cultures on day 3. Reaction with such
small quantities of H^CL allowed the generation of MOSF
sufficient to reduce plaque formation by 75%. In addition, peroxidase
substrates such as phenylenediamine, and p-aminobenzoic acid abolished
any suppressive effect of MOSF. Aune and Pierce have subsequently shown
that treatment of splenic T cells with Beta interferon induces SIRS with
the same physical and biological properties (15), and have asserted that
such interferons produce mediators that are analogous to those in the
SIRS/MOSF system. Both substances are glycoproteins with similar
molecular weights (45,000-55,000) Daltons and both are converted to
active suppressor molecules by the peroxidase activity of macrophages
(14, 15).
Nonspecific suppressor cells have been reported in tumor systems (13,
21-22). Gorczinski (21) reported a difference in the immune status of
Balb/c mice bearing progressive tumors induced by Murine Sarcoma Virus
(MSV), and mice in which those tumors had regressed. Animals bearing MSV
regressor tumors were shown to possess antigen-specific cell-mediated
immunity to the tumor. Mice bearing regressor tumors demonstrated no
such response. However, upon subjecting the progressor spleen cell
population to velocity sedimentation, active cytolytic cells could be
found. A population of cells intermediate in size was found to be
capable of suppressing macrophage migration in response to solubilized
tumor antigen(s) from both MSV and Polyoma induced tumors. Additionally,
these cells were capable of diminishing the T cell proliferative response
to phytohemagglutinin (PHA), and blocked T cell protein synthesis in
assays using tritiated leucine. Elimination of the suppressive effect
did not occur following treatment with anti-thy 1.1 antibody and
complement, but was abolished by anti-mouse immunoglobulin and complement
suggesting the functional suppressor cells were of B lineage.
Mice bearing Simian Virus 40-induced sarcomas exhibit a generalized
immunosuppression characterized by depressed lymphoproliferation to both
T and B cell mitogens, depressed anti-SRBC humoral responses (13), as
well as impaired ability to recognize and neutralize tumor cells (22).
Effectors of suppression were removed by Sephadex G-10 or plastic
adherence, implicating macrophages as mediators. Examination of cell
surface markers of lymphoid cell populations during tumor progression
revealed a corelation between tumor growth and an increase in the
proportion of cells bearing Fc receptors.
Antigen Specific J_ Cell Mediated Immunosuppression .
Antigen specific immunosuppression has been investigated using
several antigens and haptens. The T cell mediated suppressive response
to keyhole limpet hemocyanin (KLH) (23) 4-hydroxy-3-nitrophenyl acetyl
(NP) compounds (12) , and SRBC have been reviewed extensively. The use
of haptens has produced significant advances in our knowledge of
immunosuppression. First, antibody responses and idiotypes to these
substances have been thoroughly studied. The use of haptens provides
exquisite means to study specificity. KLH conjugated with dintrophenyl
hapten (DNP) directed T suppressor factors react only with KLH-DNP and
not KLH-egg albumin conjugates (23). Hapten use further allows assays of
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both T and B cell responses. Suppression of hapten-specific responses
has been measured by contact sensitivity, delayed type hypersensitivity,
cytolytic T cell responses, or immunoglobulin production (12). Since
suppressor T cell induction pathways have been formulated from hapten
specific systems, further discussion will be largely confined to KLH and
MP systems.
In NP, KLH, and other T suppressor cell systems at least 2 distinct T
suppressor cell subsets have been identified. These T lymphocytes
function in a sequence often referred to as the suppressor cell cascade.
The major differences amoung these populations include their Lyt
phenotype, functional properties, and binding specificity. The advent of
T cell hybridomas by fusion of selected T cells with the AKR thymoma BW
5147 has permitted careful analysis of each suppressor cell subset.
However, simultaneous analyses in different systems has produced a
confusing nomenclature. Green (25) has described afferent and efferent
components of a suppressor circuit generated to SRBC as having inducer,
transducer and effector components. Addition of inducer cells to in
vitro sensitization to SRBC results in the elimination of the
hemolytic plaque forming response. However, the activity of this cell
population is dependent on a second population of cells known as
transducer cells that transfer the signal from the inducer population to
the effector population. Dorf and Benacerraf (12) have described cell
populations in the NP system with the same functions but termed Ts,
,
Ts^, Tso respectively. The soluble factors produced by these
subsets are designated TsF,, TsF
2
, TsF-. For brevity, Ts
nomenclature will be used throughout this paper.
Ts, , the Inducer Population .
To define the nature of cells required for Ts, induction, Sherr
et al (26) injected mice with graded numbers of antigen-coupled syngeneic
spleen cells. A trinitrophenyl conjugate of fowl gamma globulin
(TNP-FGG) was prepared and coupled to thymocytes, adherent peritioneal
exudate and spleen cells, and splenic B cells. Mice were injected with
various quantities of these conjugated cells. After seven days mice were
sacrificed and spleen cells obtained from each group were transferred to
normal recipients, followed by immunization with TNP-FGG in pertussis
adjuvant. Eight days following this treatment results were read by
hemolytic plaques generated against TNP-FGG coupled SRBC. Only the
adherent cell populations produced significant reduction of IgG and IgM
plaque forming responses. Treatment with Qa antibody did not alter
antigenic nonresponsiveness showing that the induction of Ts, did not
require antigen presentation in the context of Qa as required by T helper
cells (Th).
Phenotypic characterization of cells responsible for Ts,
induction was further explored by others in the NP system. Cell surface
studies of the adherent cells showed they lacked Thy 1.1 and Lyt markers,
but carried la determinants(12). Functionally these cells were resistant
to 500R gamma irradiation and treatment with cyclophosphamide. Induction
of Tsj also required antigen presentation in the context of H-2
determinants. Thus I-J homology was required to induce Ts,
.
The phenotypic markers of Ts, cells correlate suppressor inducer
function with an Ly l+ ,2~, I-J+
,
Qa 1+ , surface profile
(25-28). Ly 1 markers are also found on T cells (helper) that activate
macrophages in inflammation, stimulate antibody production by B cells,
and activate cytotoxic T cells. Ts, hybridomas bear I-J cell surface
markers and constitutively secrete protein products capable of inducing
resting Ts£ hybridomas to produce suppressor factors in KLH systems
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(28). These observations have been confirmed in NP systems (27).
Hybridoma-derived TsF. was capable of the induction of Ts 9
suppressor cells in the absence of exogenous antigen. In vivo this
induction process requires 4-6 days, accounting for the fact that
TsF. must be administered early in immunization to observe the
suppressive effect (29). Thus Ts. cells are known as suppressor
inducer cells that operate in the afferent arm of antigen specific T cell
mediated immunosuppression.
Further study of TsF. (28) showed it to be bound to antigen in
the absence of H-2 gene products, and reactive in a genetically
restricted manner with cells of identical I-J haplotype. These two
properties, specificity and restriction, were attributed to two
polypeptide chains of TsF; a KLH binding heavy chain, and an I-J
light chain. The molecular weights of these chains were determined to be
45 Kd and 28 Kd respectively. These results were confirmed by injection
of IIS and 13S mRNA into xenopus laevis oocytes. The resultant
translational products were reconstituted to produce active TsF. with
the same physical characteristics. Both polypeptide chains were required
for Ts„ induction.
Ts_
2
Cells and Factors
.
Using the NP hapten system Aoki (30) has further investigated Ts,,
induction. Normal splenocytes were pulsed with hybridoraa derived
TsF. in vitro . Six days following the pulse these cells were
transferred to mice and immediately challenged with NP conjugated to
succinamide. On the fifth day after priming NP was administered to
shaved abdomens to measure contact sensitivity. The data indicated that
TS2 cells could be induced to suppress NP contact sensitivity.
Spleen cells treated with supernatants of BW 5147 were incapable of
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suppressor induction. Suppressor populations failed to induce
suppression in mouse strains that were not H-2 compatible. Depletion of
plastic adherent cells in vitro , before exposure to TsF. , also
abolished the suppressive effect in syngeneic mice. To directly
demonstrate the presence of I-J gene products on TsF. presenting
cells, adherent cells were treated with anti-I-J alloantiserum and
complement to lyse the critical cell population. Such treatment resulted
in total loss of suppressive effects.
Thus, splenic cells responsible for the presentation of TsF.
appear to be macrophages. They adhere to plastic and lack the Thy 1.1
marker (30). These cells apparently present TsF, in the context of
I-J to Ts
2
cells phenotypically characterized as Ly 1 ,2
,
I-J
+
,
Qa+ T lymphocytes (25).
As Ts, cells differ radically from Ts« cells, so do
suppressor factors obtained for separate cell populations.
Immunochemical and biological characterization of TsF~ was performed
by Dietz (31). TsF. and TsF
2
were found to differ in their
abilities to suppress immune animals. Treatment of mice immune to
azobenzenearsonate (ABA) with TsF. did not suppress delayed
hypersensitivity to ABA when administered two days after priming, while
administration of TsF„ did. Using cell panning methods and
immunoabsorbent columns, Ts 2 and TsF„ were not removed by antigen
binding. However, suppressive activity was lost when cells or factors
were passed over plates or columns treated with idiotypic IgG. The
suppressor factor obtained from Ts
?
cells (TsF„) is therefore
characterized as antiidiotypic without antigen binding capacity. This
observation has been confirmed in the NP system (32).
Tsq Cells and Factors .
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Sy and associates (33) analyzed the suppressor T cell circuit in 1
Fluro-2,4-dinitrobenzene (DNFB) contact sensitivity. To induce
suppression, mice were sensitized with supraoptimal doses of DNFB by skin
paintings twice daily. One group of these animals received intravenous
injection of 200 mg/kg cyclophosphamide (Cy) four days after the last
painting. Adoptive transfer of single cell suspensions of draining lymph
nodes from Cy treated animals did not affect contact sensitivity to DNFB
as measured by ear swelling. Cells from those mice left untreated
suppressed the degree of ear swelling. In addition, mice given graded
doses of Cy showed a dose-response curve in ability to suppress contact
sensitivity. Further evidence showed that this cell population was not
present in normal animals, but required antigen sensitization. These
results were interpreted to indicate the existence of an effector T cell
subclass in the suppressor pathway. The induction of this cell in the
course of conventional immunization was sensitive to cyclophosphamide.
This cell which they termed T auxiliary, is the equivalent of Ts- in
the NP system (12).
To further study Ts, in the NP system Sunday (34) sensitized
BIO. BR splenocytes with NP and injected into syngeneic recipients. Six
days later splenocytes form these mice (termed NP-tolerized spleen cells)
or control spleen cells from normal mice were transferred intravenously
into mice either in the induction phase or effector phase of NP specific
contact sensitivity responses. Tolerized spleen cells, but not normal
splenocytes, were capable of completely suppressing NP contact
sensitivity at either the afferent or efferent limb. Elimination of
suppression with antibody and complement showed that the cells
responsible for this effect are phenotypically Ly 2.2+
,
and Thy
1.2 . The authors concluded that these cells were functionally
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different from Ts., since administration of Ts. , or TsF. , in
the effector phase of contact sensitivity could not abrogate the
response. The authors suggested that the Ly 2.2 phenotype for this cell
was inconclusive, since treatment with Ly 2.2 antibody and complement
removed some of the suppressive effect of Ts, cells.
Is,, hybridomas that constitutively produce TsF„ have been
obtained in the NP system (35). Following HAT selection and cloning,
hybrids were screened using anti-I-J alloantiserum and further tested for
the ability to suppress in_ vivo contact sensitivity responses. To
compare this series of T suppressor factors with Ts. and Ts-
derived hybridoma factors, the authors determined when each factor was
active in the course of an immune response. TsF, only demonstrated
suppressive activity when administered during the induction phase of the
immune response, and TsF., in both afferent and effector phases.
Immunoabsorbtion studies confirmed that the suppressive activity of
TsF., could be removed by anti-I-J antisera and antigen.
Taniguchi (36) has shown that a KLH specific TsF- consists of a
molecular dimer composed of an I-J bearing chain (28 Kd) and an antigen
binding chain (35-45 Kd). Reduction of NP specific TsF, does not
destroy biological activity (12).
Antigen Specific J_ cell Mediated Suppression in Tumor Systems .
A central problem in tumor immunology is to explain the growth of
apparently immunogenic tumors. While it is possible that tumor
progression could be linked to blocking antibodies (37),
immunosuppressive molecules produced by tumor cells (38), or weak tumor
specific transplantation antigens (39) , it has become increasingly
evident that tumors can progress via the induction of specific T
suppressor cells. Functional T suppressor cells (40-42) and soluble
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factors (43-44) have been reported in tumor systems.
Methylcholanthrene (MCA) induced tumors have been shown to progress
via the action of T suppressor cells . Greene and Perry have studied the
specificity of the cytotoxic and suppressive response to the MCA-induced
1509a and a closely related tumor in A/J mice, SAI. Effector cells of
animals immune to 1509a were also capable of responding to SAI. To test
the possibility of crossreactive immune suppression, mice hyperimmune to
1509a were challenged with 10 cells of either 1509a or SAI or with
both 1509a and SAI in a double challenge. This latter group, which
received the double challenge, also received 3 x 10 thymocytes from
animals bearing 7 day 1509a tumors. 1509a induced suppressor T cells
were capable of blocking the immune response to 1509a, but not SAI, even
when both tumors were injected into the same mouse. However, 1509a
nonsuppressed immune mice responded equally well to both tumors. These
studies were carried further to include suppressor extracts obtained by
freeze-thawing thymocytes from mice bearing 1509a or SAI tumors.
Extracts were found to be specific for each of the respective tumors.
Mice hyperimmune to SAI were challenged with SAI cells on one side and
1509a cells at a second site using a protocol analogous to that
previously described. SAI induced suppressor cells limited effector
reactivity to SAI, but not 1509a.
Immunochemical studies of 1509a-induced TsF obtained in a similar
manner have been performed (43). TsF were passed over an immunoabsorbant
prepared by coupling anti-I-J antisera to Sepharose. Passage over
the column resulted in the loss of suppressive activity. Furthermore,
the suppressive activity could be recovered by 3 M KCL elution from the
relevant immunoabsorbent. Factors were also shown to bind antigen, and
could be removed from solution by absorbtion with lymphoid cells from
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normal and tumor-bearing hosts. To examine the possibility that this
might reflect an intermediate step in the generation of suppression,
1509a TsF was administered to mice daily for 4 days. On the fifth day
animals were sacrificed and their spleen cells were transferred to
tumor-immune syngeneic mice followed by tumor challenge. Suppressor
factor-induced suppression exhibited a potency equivalent to that of
tumor-induced suppressor cells, suggesting that these factors are capable
of stimulating a population of cells in normal animals with the capacity
to block tumor regression.
North and Bursuker performed additional experiments using the MCA
induced tumor, Meth A (45). Progressive growth of the Meth A
fibrosarcoma results in the generation and subsequent loss of concomitant
immunity, defined as the aquired ability of a host with a progressive
tumor to inhibit the growth of a challenge implant of the same tumor
given at another site. BALB/c mice with progressive Meth A tumors were
challenged with Meth A 3, 6, 9, 16, and 20 days following primary tumor
challenge. Mice receiving secondary challenge on days 6 and 9 rejected
the second Meth A challenge while the primary Meth A tumor progressed.
To determine the cell type responsible for concomitant regression spleen
cells were transferred from 9 day tumor-bearing hosts to mice that had
received a primary tumor challenge 3 days earlier. Such transfer
resulted in regression of the 3 day tumor, provided that the host had
received a sublethal dose (500 R) of gamma irradiation. The ability of
transfers to cause tumor regression was abolished by treatment of the
transferred population with Ly 2 antibody and complement, but not by Lyl
antibody and complement. To determine if failure to induce concomitant
immunity by passive transfer after day 14 was due to the presence of T
suppressor cells, spleen cells from mice bearing 3, 6, 9, 12, 15, or 18
16
day tumors were tested for the capacity to inhibit spleen cells from
immunized donors to cause regression in thymectomized recipients.
Suppressor T cells were infused into thymectomized recipients 3 hours
after transfer of immune cells. Suppressor T cells harvested after day
9 blocked regression produced by transfer of immune splenocytes.
Furthermore, appropriate deletion experiments with antibody and
complement showed that the cells responsible for the transfer of
suppression were Ly l+2" T cells. The authors concluded that
progressive tumor growth evokes a mechanism of concomitant immunity
produced by Ly 1 2 cytotoxic cells that is down-regulated by Ly
1 2 T suppressor cells. In a subsequent study (46) it was
shown that spleen cells from mice bearing tumors excised after the
sixteenth day were capable of suppressing immune responses in identical
assay systems. This study confirmed the Ly 1 2" phenotype.
Suppressor cells from syngeneic P815 mastocytoma-bearing DBA/2 mice
that inhibit the _in vitro generation of specific anti-tumor
immunity cytotoxicity have been reported (47). Specificity of these
cells was demonstrated when suppressor cells failed to inhibit cytotoxic
responses to syngeneic L1210 leukemia. Treatment with Thy 1.1 antibody
and complement almost completely eliminated the suppressive response
while treatment with anti-mouse IgG and complement or carbonyl iron
adherence did not affect suppression
Chronic exposure of mice to ultraviolet irradiation results in a
systemic suppression altering the animals ability to reject highly
antigenic UV-induced regressor tumors (48-50). Suppression of the immune
response in UV-irradiated mice has been shown to be directed by T cells
(48, 50). Roberts (51) observed that normal mice which had rejected
several sequential implants of a regressor tumor exhibited
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crossprotective immunity when later challenged with one of several
progressor tumors. Adoptive transfer of spleen cells, from mice
hyperimmune to regressor tumors, into UV-irradiated hosts resulted in the
transfer of specific immunity, but did not result in transfer of
crossprotection. When selected suppressor cells from UV treated mice
were passively transferred to hyperimmune syngeneic mice given 450 R
gamma irradiation to block primary immune responses, crossprotective
immunity was not detected and tumor specific immunity was observed.
These results led to the conclusion that T suppressor cells induced by
UV-irradiation were directed against common tumor associated antigens.
While the suppressive effects of UV irradiation are well documented,
the mechanism of continued growth of UV-induced progressor tumors has not
been investigated. Immunization of mice with non-dividing progressor
tumor results in regression of the homologous tumor in in_ vivo
protection assays. It is not known how an apparently immunogenic tumor
progresses despite the presence of immunogenic transplantation antigens.
This study was undertaken to determine if UV-induced progressor tumors
escape immune destruction by the induction of an active T suppressor
population.
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ABSTRACT
Murine UV-induced fibrosarcomas have been described as exceptional in
that they are highly antigenic, and most are rejected upon
transplantation into normal syngeneic hosts due to the production of
cytotoxic T lymphocytes directed toward the immunodominant tumor specific
transplantation antigen. A few of these tumors progress upon
transplantation to normal hosts; however, immunization with mitomycin C
treated progressor tumors results in immunity to challenge with the
immunizing tumor line. One rationale used to explain the continued
growth of a highly antigenic tumor is the presence of T suppressor cells.
Adoptive transfer of splenic T lymphocytes from C3H/HEN (MTV~) mice
bearing 14 day tumors to normal syngeneic mice, prior to tumor challenge,
resulted in enhanced rates of tumor growth. The suppressor cells were
characterized as being labile in vitro , sensitive to
cyclophosphamide and irradiation, and sensitive to treatment with
anti-I-J antibody and complement. Adoptive transfer of T cells from
tumor bearing animals to immune animals resulted in progressive tumor
growth. Specificity controls suggest that the T suppressor cell is
directed toward a tumor associated transplantation antigen common to
UV-induced fibrosarcomas, but not present on related
methylcholanthrene-induced tumors
.
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INTRODUCTION
The majority of tumors induced by chemical or physical agents grow
progressively upon transplantation to normal syngeneic hosts (1).
Appropriate immunization and challenge experiments have shown that such
tumors can induce transplantation immunity and thus contain tumor
specific transplantation antigens (TSTA) (2). While it is possible that
tumor progression could be linked to weak TSTA (1), blocking antibodies
(2), immunosuppressive molecules produced by tumor cells (3), or
antigenic modulation (4) , a great amount of evidence indicates that
immunoregulatory responses by the host play a major role in tumor
progression (5-9).
UV-induced tumors have been described as unique or exceptional in
that 75% are rejected when transplanted to normal syngeneic hosts (10).
The rejection response has been well documented and shown to be mediated
by the production of cytotoxic T lymphocytes (Tc) specific for the
immunodominant TSTA unique for each tumor (11-14). We have recently
characterized those UV-induced tumors that grow progressively by
comparing progressor host-tumor interactions with those of regressor
UV-induced tumors (15). Progressive UV-induced tumors were found to
possess tumor associated transplantation antigens (TATA) demonstrable
only upon hyperimmunization. The immune response was shown to be
activated in tumor-bearing hosts since cultures of tumor-bearer splenic T
cells would protect against tumor challenge in a Winn assay. The
production of Tc for progressor tumors were inhibited in transplanted
normal hosts. This study shows that suppressor T cells (Ts) are induced
following tumor transplantation in normal syngeneic hosts and the
presence of Ts correlate with tumor progression.
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MATERIALS AND METHODS
Mice. Female inbred C3H/HEM (MTV") were obtained from
Charles River Breeding Laboratory (Wilmington, MA) or bred in our
laboratory from breeding stock supplied by Veterinary Resources Branch of
NIH or Charles River. For individual experiments all animals were age
matched and 7-10 weeks of age at the onset.
Tumor cell lines. The 1422 and 2237 tumors used in these
experiments were fibrosarcomas induced by UV irradiation in C3H/HEN
(MTV ) mice (10), adapted to tissue culture, and grown as monolayers
in tissue culture flasks with Eagle's minimal essential medium containing
10% fetal bovine serum, L-glutamine, and penicillin-streptomycin (CMEM)
(11). Specificity controls were performed using 2331, a
methylcholanthrene-induced fibrosarcoma, also maintained in CMEM. All
cells were grown at 37 C in a humidified atmosphere containing 5%
CO2. Cell lines were used from passages one through fifteen after
recovery from frozen stock.
Immunization protocol. Tumor cell lines were incubated for 30
minutes in Hank's balanced saline solution (HBSS) containing 25 ug/ml
Mitomycin C (Sigma Chemical Company, St. Louis, Mo.), and recovered in
CMEM. Cells were then washed three times in HBSS, and counted by trypan
blue exclusion in a Neubauer hemacytometer. Mice were injected with 1 x
10 cells of the appropriate line and allowed to rest 30 days before
adoptive transfer or tumor challenge.
Isolation of J_ cells. Splenic lymphocytes were prepared as
previously described (11). Splenic T lymphocytes were isolated by nylon
wool column incubation and and elution as described by Julius (16)
without significant modification.
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Microcytotoxicity test. The Rb post-label
microcytotoxicity test was used as previously described (11, 15).
Cyclophosphamide (Cy) treatment of mice. The method of Glaser
was employed (17). A dose of 100 mg/kg body weight Cy (Sigma Chemical
Company, St. Louis, Mo.) was administered i.p. to normal mice 2 days
prior to tumor challenge.
Total body irradiation of mice. Normal mice were given 450R
from a cobalt source (AECL gamma irradiator, Atomic Energy Commission of
Canada, Ltd.) at times indicated relative to challenge with tumor cells.
Adoptive transfer of T lymphocytes. Splenic T cells from
normal, immune, and 14 day tumor-bearer hosts were injected i.v. or i.p.
into normal and immune syngeneic mice. Mice were challenged on the same
day with homologous or heterologous tumor cells s.c. as indicated. Tumor
growth was measured by the product of two diameters three times weekly
for 40 days.
Anti-I-J— and complement treatment of transferred cells.
WF8.A12.4 (anti-I-Jk ) and WF9.11.6 (anti-I-Jb ) ascites were
obtained from Dr. Carl Waltenbaugh, and tested for toxicity and
complement activity in Terasaki plates by trypan blue exclusion as
adapted from Garrotta and Neri (18). Before transfer to normal recipient
mice, spleen cell suspensions (2 x 10 /ml) were incubated for 60
minutes at 4 C with a 1:125 dilution of either anti-I-J or
anti-I-J ascites in Eagle's minimal essential medium containing 20
mM HEPES and 0.3% bovine serum albumin (cytotoxicity medium). Following
incubation cells were washed, resuspended at the initial concentration in
cytotoxicity medium containing a 1:12 dilution of purified rabbit
complement (Cedarline Laboratories) and incubated 1 hour in a 37°C
water bath. Remaining cells were then subjected to nylon wool passage as
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described above.
Statistical analyses. The differences between the mean tumor size
of experimental and control groups were determined by independent
analysis using the student's T test.
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RESULTS
Adoptive Transfer of Immune Suppression
The first analysis of the immune response leading to tumor
progression was an adoptive transfer of T lymphocytes from normal,
immune, and tumor-bearer hosts to normal syngeneic mice followed by
challenge with homologous UV-induced tumor lines. T lymphocytes isolated
by nylon wool passage were transferred to normal syngeneic mice by i.v.
injection. A tumorigenic dose of progressor UV-induced tumor cells was
then injected s.c. and tumor growth measured. T lymphocytes from immune
mice transferred transplantation immunity to normal recipients such that
tumor challenges were rejected (Figure 1). Tumor-bearer T lymphocytes
transferred to normal mice led to enhanced tumor growth over the controls
which received T lymphocytes isolated from normal mice.
Characterization of Ts Lymphocytes.
An analysis was then made for the presence of Ts lymphocytes in
animals with progressing tumors, taking advantage of the properties that
have previously been ascribed to these cells. Suppressor T cells have
been characterized as being short lived in vitro and their
induction in vivo sensitive to cyclophosphamide and irradiation
(17, 19). Spleen cells from tumor bearing hosts were placed into in
vitro culture without the homologous antigen, and the resulting T
lymphocytes were tested for cytotoxicity in the Rb post-lable assay
at 24 hour intervals. Culture of spleen cells from tumor-bearer mice led
to the production of cytotoxicity in the absence of tumor cells or
antigen (Table 1). Lymphocytotoxicity was absent at day 0, present at
day 1, and increased over days 2 and 3.
The effects of cyclophosphamide on Ts cell induction in vivo
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were tested using the procedure of Glaser (17). Mice were pretreated
with cyclophosphamide two days prior to tumor challenge and compared to
untreated challenge recipients for tumor progression. Tumors progressed
in challenge controls but were rejected in cyclophosphamide treated
challenge recipients (Table 2). Furthermore, regressor mice were
determined resistant to further challenge with the homologous tumor line.
The effect of whole body irradiation on the induction of Ts cells by
progressor tumor cell challenge was then tested. Mice were challenged
with progressor tumor cells from 1 hour before to 6 days after
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irradiation with 450R from a Co source. Tumor regression appeared
as a result of recipient irradiation and was dependent upon the time of
irradiation (Table 3). Tumors regressed when recipient animals were
exposed to 450R 4 days after tumor challenge, and approximately half
regressed when mice were irradiated 6 days post challenge. Those mice
resistant to first tumor challenge remained resistant to further
challenge with the homologous tumor line. The effects of 450R were not
on the tumor cells themselves since cultured tumor lines routinely
require 5,000 R to halt cell division as measured by tritiated thymidine
incorporation.
An experiment was then performed to attempt to relate radiation
induced tumor regression to the loss of radio-sensitive T cells. Mice
were challenged with tumor cells and were irradiated on day 4. Normal
and tumor-bearer splenic T-cells were then adoptively transferred to
irradiated animals. While transfer of normal T cells had no effect on
radiation induced tumor regression, transfer of tumor-bearer T cells led
to tumor progression (Table 4).
Suppression of Immune Animals
To provide further evidence of the involvement of Ts as mediators of
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progression of UV-induced tumors and to demonstrate specificity, adoptive
transfers to immune animals were performed. Tumor-bearer or normal T
lymphocytes were injected either i.v. or i.p. to immune mice followed by
s.c. challenge with the immunizing tumor line. Control groups consisted
of adoptive transfer of tumor-bearer splenic T cells obtained from
animals bearing the heterologous UV-induced tumor line or mice bearing
the methylcholanthrene-induced tumor 2331, as well as T cells from normal
animals. Tumor measurements were made over a period of 3 to 4 weeks.
In each case, the the number of animals bearing tumors was higher in
hosts injected with T lymphocytes from mice bearing UV-induced progressor
tumors (Table 5). Furthermore, in comparison of the relative growth
rates of tumor-bearers between control and experimental groups,
significantly higher growth rates were obtained from the administration
of T cells from mice bearing UV-induced tumors (Figure 2). Approximately
80% of mice receiving T lymphocytes from mice bearing 2331, or normal
splenic T cells rejected tumor challenge within 18 days.
Adoptive Transfer of I-J— Deleted T Lymphocytes
.
Experiments previously described in this paper implicate Ts
lymphocytes as mediators of progression of UV-induced tumors in normal
hosts. Elimination of suppressor function by anti-I-J alloantiserum
and complement would confirm Ts lymphocytes as cells mediating immune
non-responsiveness to UV-induced progressor tumors. Suspensions of
splenic leukocytes from hosts bearing UV-induced tumors were reacted with
k b
either anti-I-J or anti-I-J antibody, washed, treated with
purified rabbit complement, and recovered following nylon wool passage.
Suspensions of T lymphocytes treated with anti-I-J antibody with
specificity for Ts lymphocytes from mice with H-2 background failed
to show the suppressive effect (Figure 3). Conversely, spleen cell
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suspensions left untreated or exposed to anti-I-J antibody and
complement clearly demonstrated enhanced tumor growth.
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DISCUSSION
In syngeneic hosts, murine UV-induced progressor tumors stimulate
immune responses that mediate the growth of tumor transplants. Previous
experiments (15) have demonstrated that these progressor tumors possess
TATA and that hosts bearing progressive tumors have undergone
sensitization to these antigens. Even though active effector Tc are not
found in tumor bearers, T cell sensitization does occur since Tc cells
are demonstrable following spleen cell culture without the addition of
antigen. Similarly, tumor-bearer T cells can function in adoptive
transfer of immunity in a Winn assay. Thus, the block or suppression of
the immune response to UV-induced tumor antigens occurs after antigen
sensitization or T cell activation, but prior to the development of
effector Tc. This apparent block in the development of Tc may be due to
the presence of Ts cells which block a differentiation or regulatory step
in the Tc induction pathway. Alternatively, Tc function could be blocked
due to release of a factor such as antigen.
The experimental evidence presented in this paper identifies the
blocker as a T suppressor cell (Ts). First, i.v. or i.p. adoptive
transfer of nylon wool nonadherent spleen cells obtained from 14 day
tumor bearing hosts in conjunction with tumor challenge enhanced the
growth of the homologous tumor. In marked contrast, T cells obtained
from immune animals and adoptively transferred resulted in tumor
regression, while transfer of normal splenic T cells had no effect on the
rate of tumor progression. The suppression was then shown to be labile
in vitro
,
sensitive to cyclophosphamide and irradiation, all of
which are properties of Ts cells. Furthermore, rejection induced by
irradiation of progressor-challenged mice could be inhibited by adoptive
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transfer of tumor-bearer splenic T cells. Second, immune recipients of
such adoptive transfers were rendered susceptible to progressive tumor
growth. Finally, treatment with antibody directed at the protein product
of the J subregion of the I gene in C3H mice (anti-I-J ) and
complement abolished the suppressive effect of adoptive transfers to
normal animals, and treatment with anti-I-J antibody failed to
alter the suppressive effect. Thus, tumor progression in the later
stages was directly linked to cells bearing I-J markers, i.e., Ts
cells.
Chemically-induced and spontaneous skin tumors growing jLn_ vivo
generally have been shown to progress by the action of Ts cells (5-9,
19). The majority of murine skin tumors induced with ultraviolet light
are highly antigenic and incapable of progressive growth unless the host
has been immunocompromised. Fisher and Kripke (20) have shown that
subcarcinogenic doses of UV light induce Ts which allow progressive
growth of regressor fibrosarcomas, and that observation was independently
confirmed by Daynes and Spellman (21). In addition, passive transfer of
splenic T cells from mice exposed to low doses of UV-irradiation
facilitated regressor tumor growth. Subsequently, it was reported that
UV-induced T suppressor cells were directed toward TATA common to
UV-induced tumors (22). Further evidence of Ts in UV-induced tumor
systems was obtained by Roberts (23) who established a continuous cell
line (UV1) capable of suppressing in vivo , responses to syngeneic
regressor tumor lines.
The results presented here show that UV-induced progressor tumors
activate Ts in a similar manner. The contrasts between regressor and
progressor tumors are that the regressors possess TSTA which induce Tc
and subsequent tumor rejection (10-14), while progressors possess tumor
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antigens (TATA and/or TAA) which induce Ts and tumor progression (15).
Although the tumor antigens of progressors can function as TATA following
multiple immunization with non-dividing tumor cells, it has been
suggested that tumor might activate the Ts pathway by shedding surface
antigens into the circulation, thereby bypassing antigen presentation
(19, 24). Supraoptimal quantities of antigen could lead to high zone
tolerance, shown to be mediated by Ts (25-26). Alternatively, certain
epitopes may selectively activate the suppressor cell pathway as has been
shown with myelin basic protein, egg lysozyme, and galactosidase (27-29).
While the effector cells mediating regression (Tc) and progression
(Ts) are well documented, the antigenic determinants inducing each are
ill-defined. Studies using regressor UV-induced tumors have suggested
three types of antigens; TSTA, TATA, and TAA (30-31). The regressor TSTA
are immunodominant and responsible for Tc induction and tumor regression
(10-14). The growth of regressor UV-induced tumors in syngeneic UV
treated mice led to the concepts of TATA and TAA in this system, since
mice possess Ts cells induced by UV-exposure which have specificty for
common antigens on regressor UV-induced tumors (22, 29-31). Induced Ts
then block the response to the regressor TSTA leading to progression in
UV treated mice. Thus, TATA and TAA are immunorecessive and are the
proposed determinants recognized by Ts as tumors progress following UV
treatment. The results shown in Figure 3 indicate that this hypothesis
may also be applicable to UV-induced progressor tumors. T cells derived
from mice bearing 1422 tumors and those from mice bearing 2237 were
equally capable of producing a suppressive effect in animals immune to,
and challenged with 2237. Identical experiments utilizing the 1422
system show similar results, implicating TAA or TATA in the Ts induction
of progressor tumors. Previous studies have shown that both UV-induced
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progressor and regressor tumors possess TAA crossreactive with antigenic
determinants on fetal and placental cells (31). The authors felt that
these TAA are the antigens for which the UV induced Ts have specificity.
Connections between TAA or TATA common to progressor and regressor tumors
and oncofetal antigens await further study.
Although the data presented in this paper clearly support the
presence of Ts in C3H mice bearing established progressor tumors, the
mechanism of Ts induction remains unclear. Exposure of mice to
UV-irradiation induces systemic alteration in immune function including,
impairment of antigen presenting cells (23). Whether the establishment
of Ts allows progressive tumor growth, or progressive tumor growth allows
Ts induction remains a subject of debate. The data presented in this
paper, coupled with studies of the antigenic properties of regressor
tumors, suggest that UV-induced progressor tumors lack functional TSTA
while possessing TATA, and TAA. Deficiency of TSTA could allow escape
from cognitive immune function and establishment of Ts directed toward
TATA, or TAA. The antigen eliciting the suppressor response remains
unknown.
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APPENDIX 1
Studies on the Specificity of the T Suppressor Response to
UV-induced Progressor Tumors.
INTRODUCTION
Chronic exposure of mice to ultraviolet irradiation produces a
systemic immunological alteration resulting in the animal's failure to
reject highly antigenic UV-induced regressor tumors (48-50).
Immunological nonresponsiveness in UV-irradiated mice has been shown to
be directed by T suppressor cells (48, 50). Roberts (51) observed that
normal mice which had rejected several sequential implants of a regressor
tumor exhibited cross protective immunity when later challenged with one
of several progressor tumors. It was also found that adoptive transfer
of spleen cells from mice hyperimmunized with a regressor tumor into
UV-irradiated hosts resulted in the transfer of specific immunity and did
not result in the transfer of crossprotection. When suppressor cells
from UV-treated mice were adoptively transferred into hyperimmune mice
given 450 R gamma irradiation to block primary immune responses,
crossprotective immunity was not detected and tumor specific immunity was
observed. These results led to the conclusion that Ts induced by
UV-irradiation were directed against common tumor associated antigens.
We undertook experiments designed to gain further information on the
specificity of Ts induced by UV-induced progressor tumors. Normal mice
were challenged with one of two progressor tumors and following a period
of tumor growth were challenged with a non-tumorogenic dose of regressor
tumor cells. If indeed Ts are directed at TAA common to UV-induced
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tumors, the establishment of a growing progressor tumor might
immunocompromise the host and allow progressive growth of regressor
tumors.
The establishment of ±n_ vitro assays of T cell-mediated
immunosuppression in UV-induced systems might allow further investigation
of specificity as well as the site of action of the blocker. Frost has
recently reported the establishment of a reproducible _in_ vitro
assay for the effect of suppressor T cells on the of generation cytotoxic
T cells (Tc) to a metastatic murine sarcoma, MDAY-D2 (52). Suppressor
cells obtained from tumor-bearing hosts were shown to be capable of
disrupting the production of Tc directed at MDAY-D2 in a mixed lymphocyte
tumor cell culture (MLTC). Fujimoto (53) has reported direct cellular
interaction between Tc and Ts in a syngeneic murine sarcoma system.
Splenic T cells from animals bearing growing tumors specifically
inhibited the process of tumor cell lysis by Tc generated in MLTC in a
Cr release assay. The suppression reported was specific for the
individual tumor by which suppressor cells were generated and did not
crossreact with related sarcomas.
One proposed mechanism of T cell mediated immunosuppression was
reported by Kitamura (54) who found that the addition of interleukin 2
(IL-2) to a cloned Ts line, 3D10 enhanced the production of soluble
suppressor factors (TsF) . Further investigation showed that the Ts in
this system were more IL-2 dependent than Tc. However, TsF added to MLTC
did not block the production of IL-2, but was capable of suppressing
antigen specific proliferation. We reasoned that the addition of
exogenous IL2 to cultures of tumor-bearer spleen cells might overcome the
apparent lability of Ts ^n vitro , and allow demonstration of Ts in
culture.
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MATERIALS AND METHODS
Repressor Challenge of Mice Bearing UV-induced Progressor Tumors
.
Age matched C3H/HEN (MTV~) were injected in the right flank with
1 x 10 2237 or 2 x 10 1422 s.c. maintained in OEM as
previously described. Following 4 and 10 days of progressive tumor
growth, animals were injected in the left flank with 2 x 10
regressor tumor cells (1316 or 1591). Controls were identical groups of
animals which did not receive regressor challenge, or were injected in
the left flank with an identical dose of 3256, a
methylcholanthrene-induced regressor tumor. Tumor measurement was
reported as the product of 2 diameters over a period of 20-30 days.
Suppression of Lymphocyte Proliferation by Tumor-Bearer T Cells .
Splenocytes from animals immune to 2237 were cultured in CMEM
containing 5 x 10" M 2, mercaptoethanol (2ME) in 96 well flat bottom
plates (Costar, Inc., Cambridge, MA) at a concentration of 5 x 10
cells per well. The cells were cultured in 0.2 ml of media at 37 C
3
for 5 days in the presence of 5 x 10 mitomycin-C treated 2237 tumor
cells. Nylon wool nonadherent suppressor cells from tumor bearing hosts
were added on day at a suppressor to responder cell ratio of 1:1 unless
otherwise stated. Cultures were harvested at the indicated intervals
with a Titertek Cell Harvester(Flow Laboratories, Rockville, MD.) and
counted in a Beckman LS 230 liquid scintilation counter. Cytotoxic
responses were measured on day 5 by Cr release assay.
Assay of Cell Mediated Cytotoxicity (CMC) .
Tumor cells were labelled with Cr by incubating 2 x 10
cells in CMEM containing 100 uCi of Na
2
51
Cr0
4
(New England
Nuclear) for 70 minutes in a 37 C water bath. Alternatively, cells
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were incubated overnight in 3 ml CMEM containing 300 uCi
Na£ CrO^. After labeling cells were washed 3 times in 10 ml
of HBSS and resuspended at appropriate concentrations in CMEM containing
20 mM HEPES. All samples were run in quadruplicate and incubated at 37
C in a 5% (XL incubator for 18 hours. Plates were the
centrifuged at 300 g for 10 min. and 100 ul of the supernatant were
transferred to vials and counted in a Packard Multi-Prias 1 gamma
counter. The percentage of specific chromium release was calculated as:
experimental release - spontaneous release
total release - spontaneous release
Blocking of the cytotoxic response was performed by the addition of T
cells from tumor bearer hosts at the indicated ratios to labeled target
cells 2 hours prior to the addition of Tc unless otherwise indicated.
IL-2 Block of Suppressive Loss .
IL-2 supernatants were produced by Concanavalin A stimulation of rat
splenic T cells and were the kind gift of Phil Streeter of our
laboratory. Splenic leukocytes from mice bearing 1422 or 2237 UV-induced
tumors were placed in culture without antigen in CMEM containing 2 ME and
40% IL-2 supernatants by volume. Cultures were harvested daily,
subjected to nylon wool filtration, and assayed for cytotoxicity against
the homologous tumor line in a Cr release assay previously
described. Heterologous UV-induced tumors and methylcholanthrene-induced
2331 were used as specificty controls where indicated.
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RESULTS
Regressor Challenge of Mice bearing UV-induced Progressor Tumors .
No progressive growth of regressor tumors was noted in animals
bearing 1422 or 2237 progressor tumors for 4 or 10 days prior to
regressor challenge (table 6,7). These results would apparently indicate
that Ts induced by progressor tumors are directed toward an antigen not
present on UV-induced regressor tumors. Although regressor tumors
consistently persisted for a longer time than did control groups that
received no progressor challenge, the difference did not appear
significant. Progressor tumors persisted despite rejection of regressor
tumors.
Some crossreactivity between 1316, a regressor tumor, and 1422, a
progressor, was noted. When challenged with 1316, animals bearing 4 day
1422 tumors were capable of the rejection of both challenging lines.
This anamoly was not witnessed in animals bearing 10 day 1422 tumor
growth and was not reproducible upon repetition of the experiment.
Supression of Lymphocyte Proliferation by Tumor-Bearer T Cells .
The addition of T cells from 2237 tumor bearing hosts at a 1:1 ratio
with responder cells did not result in the suppression of lymphocyte
proliferation in an MLTC (Figure 4). Instead, the addition of splenic T
lymphocytes from tumor-bearers merely doubled the proliferative response
to tumor antigen, an effect similar to doubling the immune cell
population. Interestingly the addition of an equal number of splenic T
cells from normal animals did not heighten the response as greatly as
tumor-bearer T cells indicating that these cells were able to respond to
proliferative stimuli in a manner expected by immune lymphoid cells.
Furthermore, when tested for cytotoxicity at the end of the 5 day culture
period, cultures containing tumor-bearer spleen cells produced higher
levels of cytotoxicity (Table 8) showing a positive correlation between
proliferation and resulting killing ability. Cultures using the 1422
system produced similar results.
IL-2 Block of Suppressive Loss .
The addition of exogenous IL-2 to cultures of tumor-bearer spleen
cells was not capable of block the in vitro lability of suppressor
cells and the ensuing production of cytotoxic cells. However,
specificity controls performed on days 2 and 3 of the experiment clearly
show that the kill produced is nonspecific (Table 9). Cells recovered
from the MLTC were able to lyse both progressor lines as well as the MCA
induced 2331.
Blocking of Cell Mediated Cytotoxicity .
The addition of tumor-bearer T cells to cytotoxic cells generated
in vitro in assays of CMC failed to demonstrate any direct effector
function of Ts on Tc (Table 10). Repetition of these experiments at
various stages of tumor progression did not demonstrate suppressive
activity of Ts on Tc. Incubation of labeled targets with Ts, 2 hours
prior to introduction of Tc, failed to show any suppressive effect as
reported by Fujimoto (54).
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TABLE 1
CYTOTOXICITY OF TUMOR-BEARER SPLEEN T-LYMPHOCYTES
FOLLOWING IN VITRO CULTURE3
% CYTOTOXICITY ON HOMOLOGOUS TARGET
TUMOR AFTER DAY(S) IN CULTUREb
1 2 3
3 24 43
12 28 25
1422
2237
a. 2 7Tumors averaged 30 mm . Spleen cultures of 2 x 10 cells. Following
culture, T lymphocytes isolated by nylon wool column filtration.
Assay was performed at a ratio of 50 effectors to 1 target.
^3
TABLE 2
EFFECTS OF CYCLOPHOSPHAMIDE ON THE
PROGRESSION OF UV-INDUCED TUMORS3
DOSE OF CYCLOPHOSPHAMIDE
(mg/kg)
TUMOR CELL TUMOR PROGRESSION
CHALLENGE TUMOR-BEARERS/ TOTAL
1422 10/10
1422 1/10
2237 10/10
2237 0/10
100
100
Cyclophosphamide was injected intraperitoneally 2 days prior to tumor
challenge. Mice were challenged with a dose of 10 progressor tumor cells.
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TABLE 3
EFFECTS OF TOTAL BODY IRRADIATION ON THE
PROGRESSION OF UV-INDUCED TUMORS 3
TIME OF IRRADIATION IN
RELATION TO TUMOR CHALLENGE
No irradiation
1 hour before
2 days after
4 days after
6 days after
TUMOR PROGRESSION (TB/TOTAL)
1422 2237
7/10 10/10
10/10 9/10
8/10 9/10
1/10 0/10
4/10 6/10
Tiice were given 450R irradiation from a cobalt source.
b
Mice were challenged with 10 1422 or 2237 cells,
k5
TABLE 4
REVERSAL OF RADIATION-INDUCED TUMOR REGRESSION BY
TRANSFER OF TUMOR-BEARER SPLENIC T CELLS
TREATMENT OF
CHALLENGE RECIPIENTS*
AVERAGE TUMOR SIZE (mm2 + S.E.) b
DAY 10 DAY 20
7.0 + 1.4
7.9 + 1.4
6.0 + 1.5 8 .3 + 0.4
450 R
450 R + Normal T Cells
450 R + Tumor-Bearer T Cells
°Mice were challenged subsutaneously with 10 1422 cells on day 0; on day
4 groups of five mice were treated as described above. Recipient mice
recieved 3.5 x 10 normal splenic T cells or tumor-bearer splenic T cells
intravenously.
Tumor measurements are the averages of two diameters.
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TABLE 6
THE EFFECT OF REGRESSOR CHALLENGE OF
MICE BEARING SHORT-TERM3 PROGRESSOR TUMORS
NUMBER OF TUMOR-BEARERS
TOTAL ANIMALS INJECTED
EXISTING TUMOR LINE CHALLENGE LINE REGRESSOR PROGRESSOR
1422
1422 1591
1422 1316
2237
2237 1591
2237 1316
4/4
0/5 4/5
0/4 4/4
5/5
0/5 5/5
0/4 4/4
1422 and 2237 were allowed to progress for 4 days prior to challenge in
the opposite flank with 2 x 10 viable regressor lines.
1*8
TABLE 7
THE EFFECT OF REGRESSOR CHALLENGE OF
MICE BEARING LONG-TERM3 PROGRESSOR TUMORS
NUMBER OF TUMOR-BEARERS
TOTAL ANIMALS INJECTED
EXISTING TUMOR LINE CHALLENGE LINE REGRESSOR PROGRESSOR
1*22 5/5
1422 1591 0/5 4/5
1422 1316 0/5 5/5
2237 5/5
2237 1591 0/5 5/5
2237 1316 0/5 5/5
a
1422 and 2237 tumors progressed for 10 days prior to s.c. challenge with
2 x 10 viable regressor cells.
^9
TABLE 8
CYTOTOXICITY OF T CELLS GENERATED IN A MIXED LYMPHOCYTE
TUMOR CELL CULTURE CONTAINING ADDED T SUPPRESSOR CELLS3
PERCENT KILL
SOURCE OF ADDED SUPPRESSOR CELLS 2237 1316
None Added
Normal Spleen
2237 Tumor-Bearer Spleen
19+4
60 + 5
67+3
23 + 1
55 + 3
58 + 3
Splenic T cells were added at the culture initiation at a responder:
suppressor: stimulator ratio of 100: 100: 1.
Harvested T cells were tested for cytotoxicity in a Cr release assay
at an effector: target ratio of 40: 1.
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TABLE 10
EFFECT OF T-CELLS FROM SPLEENS OF TUMOR BEARING HOSTS
ON THE CYTOTOXICITY OF IMMUNE T-CELLS GENERATED
IN MIXED LYMPHOCYTE TUMOR CELL CULTURE
IMMUNE T-CELLS T-SUPPRESSORS ADDED 1 % KILL
ANTI-1422 NONE
NORMAL SPLEEN
TUMOR-BEARER SPLEEN
22 + 4
24 + 4
22 + 3
ANTI-2237 NONE
NORMAL SPLEEN
TUMOR-BEARER SPLEEN
44 + 5
43 + 5
42 + 5
Immune effectors were generated in an MLTC as previously described at a
responder: target ratio of 100:1.
Ef f ector: Suppressor:Target cell ratios were 20:20:1 in a chromium release
assay.
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Figure 1. Adoptive transfer of T lymphocytes from normal, immune and
tumor-bearing hosts to normal mice and subsequent challenge with
UV-induced tumor lines. T lymphocytes: 3 x 10 cells i.v.;
challenge: 3 x 10 homologous tumor cells s.c. A. 1422, differences
between groups of 5 mice were statistically significant, P < 0.001 for
days 13, 16, and 19. B. 2237, P < 0.05 for days 23 and 27.
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Figure 2a. Adoptive transfer of T lymphocytes from 14 day tumor-bearing
hosts to 1422 immune animals. T lymphocytes: 3 x 10 i.p.;
challenge: 2 x 10 viable 1422 s.c. Differences in comparison with
normal spleen (NS); 1422 TBS) P < 0.005 for days 7 through 15. 2237 TBS;
P < 0.05 for days 9 through 15.
Figure 2b. Adoptive transfer of T lymphocytes from 14 day tumor-bearing
hosts to 2237 immune animals. T lymphocytes: 3x 10 i.v.; challenge:
2 x 10 viable 2237 s.c. Differences for both 1422 TBS and 2237 TBS
in comparison to normal spleen (NS) were: P < 0.05 days 6 through 8; P <
0.025 days 8 and 10; p < 0.005 days 12 and 14.
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Figure 3a. Adoptive transfer of anti I-J depleted T lymphocytes
from 14 day 1422 tumor-bearing hosts to normal animals followed by
homologous tumor challenge. T lymphocytes: 3 x 10
7
i.p.; challenge:
2 x 10 viable 1422 s.c. Differences P < 0.005 day 4, and P < 0.025
days 7 through 15.
Figure 3b. Adoptive transfer of anti I-J depleted T lymphocytes
from 14 day 2237 tumor-bearing hosts to normal animals followed by
homologous tumor challenge. T lymphocytes: 3 x 10 i.v.; challenge:
1 x 10 viable 2237 s.c. Differences P < 0.005 days 7 through 15.
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Figure 4. Results of the addition of Splenic T cells from animals
bearing 8 day progressor tumor (2237) to Mixed Lymphocyte Tumor Cell
cultures of 2237 immune splenocytes and Mitomycin C treated tumor cells.
Results are shown as quench corrected counts of tritiated thymidine
incorporated at the appropriate time intervals. Control (C):
responder/stimulator ratio of 2237 immune splenocytes to 2237 tumor
cells, 100:1. Tumor-bearer spleen (2237 TBS): the addition of splenic T
cells from tumor-bearers at a 1:1 ratio to immune responder cells
producing a responder/suppressor/stimulator ratio of 100:100:1. Normal
Spleen (NS): normal splenic T cells substituted for TBS at a ratio of
100:100:1.
59
3H THYMIDINE INCORPORATION (CPM x I04 )
S
00
iS
^1
no
CD
roT T CJl
60
FINAL DISCUSSION
Murine UV-induced progressor tumors stimulate immune responses in
syngeneic hosts that mediate the growth of tumor transplants. Previous
experiments (55) have demonstrated that these progressor tumors possess
TATA and that hosts bearing progressive tumors have undergone
sensitization to these antigens. Even though active effector Tc are not
found in tumor bearers, T cell sensitization does occur since Tc cells
are demonstrable following spleen cell culture without the addition of
antigen. Similarly, tumor-bearer T cells can function in adoptive
transfer of immunity by a Winn assay. Thus the block or suppression of
the immune response to UV-induced tumor antigens occurs after antigen
sensitization or T cell activation, but prior to the development of
effector Tc. This apparent block in the development of Tc may be due to
the presence of Ts cells which block a differentiation or regulatory step
in the Tc induction pathway. Alternatively, Tc function could be blocked
due to release of a factor such as antigen.
The experimental evidence presented in this paper identifies the
blocker as a T suppressor cell. First, i.v. or i.p. adoptive transfer of
nylon wool nonadherent spleen cells obtained from 14 day tumor bearing
hosts in conjunction with tumor challenge enhanced the growth of the
homologous tumor. In marked contrast, T cells obtained from immune
animals and adoptively transferred resulted in tumor regression, while
transfer of normal splenic T cells had no effect on the rate of tumor
progression. The suppression was then shown to be labile in
vitro
, sensitive to cyclophosphamide and irradiation, all properties
of Ts cells. Furthermore, rejection induced by irradiation of progressor
challenged mice could be inhibited by adoptive transfer of tumor-bearer
splenic T cells. Second, immune recipients of such adoptive transfers
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were rendered susceptible to progressive tumor growth. Finally,
treatment with antibody directed at the protein product of the J
subregion of the I region gene in C3H mice (anti-I-J ) and complement
abolished the suppressive effect of adoptive transfers to normal animals,
and treatment with anti-I-J antibody failed to alter the
suppressive effect. Thus, tumor progression in the later stages was
directly linked to cells bearing I-J markers, i.e., Ts cells.
The specificity of the Ts in UV-exposed animals has been investigated
by Roberts (51, 56). Mice hyperimmunized with the regressor tumor RD 87
and challenged with two progressor lines. Immunization with RD 87
protected most animals against progressor challenge. However, adoptive
a
transfer of 1 x 10 hyperimmune spleen cells to UV-treated animals
resulted in immunity to only the immunizing tumor line, suggesting that
Ts induced by UV light were directed toward TATA and not TSTA. In other
experiments, the transfer of 3.5 x 10 nylon wool nonadherent spleen
cells into RD 87 hyperimmune animals did not inhibit the anti-tumor
response. However, such transfers into normal mice resulted in the
inability to reject challenge with the regressor tumor RD 87. Roberts
followed these experiments with similar adoptive transfers of splenic T
cells from UV exposed animals to mice hyperimmune to the MCA induced
LR-8. The results showed that UV-induced Ts were capable of blocking
immunity to LR-8. The authors thereby concluded that UV-induced Ts were
directed against TAA present on both UV and chemically induced tumors.
The -data presented here clearly do not support that hypothesis with
regard to UV-induced progressor tumors. Splenic T cells harvested from
mice bearing the MCA tumor line, 2331 were not capable of suppressing the
immune response to UV progressor tumors. Data presented in Figure 3 and
Table 5 shows no significant difference between the adoptive transfer of
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2331 TBS and the adoptive transfer of normal splenic T cells.
Furthermore, the existence of UV-induced progressor tumors for any period
of time does not allow the growth of UV-induced regressor tumors (Tables
6 and 7). Although these data are not conclusive, they suggest that that
suppressive epitopes eliciting Ts to progressor tumors are not present on
regressor tumors and thus, Ts elicited by progressor tumors is not the
same as Ts induced by UV irradiation.
Suppressor cells have been extensively studied by the use of cloned
Ts or the production of T cell hybridomas. At least one author (54) has
alluded to the fact that while these studies provide pertinent
information to the mechanism of T cell-mediated suppression, they may not
be indicative of the suppressive response in vivo . Most, if not
all, immunological responses are polyclonal. In contrast, the
immunosuppressive response has been thought to be monoclonal. The
existence of a single suppressive epitope results in the induction of
suppression and protection from immunologically mediated destruction.
However, normal and transformed cells within a syngeneic host possess a
number of common antigens, any of which may be immunosuppressive.
Therefore the possibility exists that the suppressive response may be
polyclonal, and a threshold number of suppressive epitopes may be
required to block development of cytotoxicity. It then follows that the
immunosuppressive states induced by UV-exposure and UV-induced progressor
tumors may be dissimilar. Regressor tumors may possess an insufficient
quantity of epitopes present on progressor tumors and as a consequence
are rejected in animals bearing progressor tumors. At a dose of 2 x
10 cells the regressor tumor 1316 produced palpable tumors which
eventually regressed in animals bearing progressor tumors. At that dose
1316 injected into normal controls produced tumors that could not be
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distinguished from injection scars. Although the regressor 1591 produced
tumors in normal animals, 1591 tumors in animals bearing progressors
tumors persisted for a few days longer. The existence of a polyclonal
suppressor response may explain these observations. An as yet uncloned T
cell line capable of suppressing _in_ vivo responses to a variety of
syngeneic UV-induced tumors has recently been established from
UV-irradiated BALB/c mice (57). Eventual cloning of this Ts cell line
may show the existence of such a polyclonal suppressor system.
Alternatively, the failure of regressor tumors to grow in animals
bearing UV-induced progressor tumors could be related to tumor dose.
Studies on the growth of regressor tumors in mice exposed to UV light
3
have been performed using 1 mm trocar tumor implants making
comparisons impossible. Doses of 1 x 10 viable cells delivered s.c.
produce progressive growth of 1591. A dose of 2 x 10 cells would
therefore not seem unreasonable, as higher doses could result in
progression via high-zone tolerance.
Still a third possibility could explain failure of regressor tumor
growth in progressor tumor-bearing hosts. If suppression were localized
to the anatomical area supporting progressor tumors concomitant immunity
could develop to subsequent regressor challenge through TATA. Fisher and
Kripke (48) have demonstrated that the suppressive state induced by UV
light is systemic. However, little evidence showing systemic suppression
in progressor systems exists. The observation in this paper that i.v. or
i.p. administration of splenic T lymphocytes from tumor-bearing hosts
enhances the growth of progressor tumors injected s.c. strongly argues
that the associated suppression is systemic.
The addition of splenic T cells from hosts bearing progressor tumors
failed to suppress ±n_ vitro lymphocyte proliferation of immune
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spleen cells to tumor antigen (Figure 4). Moreover, splenic T cells
shown to be suppressive in in. vivo assays apparently acted as
immune cells, doubling the proliferative capacity of immunocytes to tumor
antigen. This observation was confirmed by testing the resulting T cells
for cytotoxicity in a Cr release assay (Table 8). The increased
proliferative capacity correlated with enhanced cytotoxic activity,
although some question remains as to specificty.
In this paper and elsewhere (58, 59) Ts have been shown to be
extremely labile in vitro . However, others (52) have shown that
the addition of Ts to MLTC up to 48 hours from the onset of culture is
capable of abrogating the proliferative and cytotoxic response to tumor
antigen. The function of the antigen presenting cell (APC) has been
shown to be intimately involved in the induction of Ts in UV-irradiated
animals (60, 61). Briefly, adherent trinitrophenyl-derivatized cells
from peritoneal exudate cell population or the spleen of UV-treated
donors could not induce hapten-specific delayed hypersensitivity
responses in UV-irradiated mice, whereas adherent
trinitrophenyl-derivatized cells from normal donors were able to do so.
This evidence led to the proposal that antigen presentation is affected
by UV treatment in a manner that stimulated Ts.
In light of such evidence, it is a reasonable hypothesis that if
UV-induced progressor tumors induce Ts in a similar manner, then the
addition of Ts to cultures of immune spleen cells and antigen would
result in normal antigen presentation, and proliferation against tumor
antigen ensues. This hypothesis is weakened however, by reports that
these experiments could not be repeated using tumor antigen (62).
Despite apparent weakness of this hypothesis, separation of APC by
adherence may not result in efficient macrophage deletion and antigen
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presentation could be accomplished by a minor contaminating population.
Thus, antigen presentation by functional immune macrophages remains a
possibility.
It would seem more likely that some factor contained in culture
selectively acted against Ts. Suppressor T cell lines have been shown to
produce soluble protein products which have been designated T suppressor
factors (TsF) (36). TsF were subsequently shown to be composed of two
polypeptide chains linked by disulfide bonds that could be separated by
treatment with the reducing agent dithiothreitol (12). The addition of 2
ME to MLTC then may have inactivated such suppressor factors yielding
proliferation and cytotoxicity. It must be noted, however, that in the
same experiments (12) separated TsF polypeptide chains were still capable
of inducing suppression unless they were further modified by alkylation
with iodoacetamide.
The data obtained from MLTC proliferative responses become more clear
when examined in light of the data presented in Table 9. The cytotoxic
cells resulting from culture of spleen cells from tumor-bearing hosts do
not demonstrate specificity. On day 3 of culture nylon wool nonadherent
cells obtained from the MLTC were capable of lysing not only UV-induced
progressor tumors, but also showed a similar amount of activity against
the MCA line 2331. This raises the possibility that the effector cells
responsible for the cytolytic activity are Natural Killer (NK) cells and
not Tc. It is then possible that in MLTC the proliferative response
observed is due to the generation of NK cells while proliferation of
antigen specific Tc is blocked. This evidence is further substantiated
by others in our laboratory who have not been able to demonstrate Tc in
mice immunized with progressor UV-induced tumors.
The addition of exogenous IL-2 did not alter the associated loss of
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suppression in_ vitro (Table 9) . Kitamura had previously shown that
addition of IL-2 to cultures of a cloned Ts resulted in enhanced
production of TsF (54). Although cytotoxicity was still observed, it was
nonspecific as previously discussed. Similar cultures of spleen cells
from normal mice do not produce the associated cytotoxic activity
indicating that some exposure to antigen is required for the response.
Therefore it would seem that Ts in this system are capable of suppressing
the antigen specific immune response, but incapable of suppressing
non-specific responses. Furthermore, the addition of tumor-bearer T
cells to mixtures of these cytotoxic cells and radiolabeled targets did
not demonstrate the ability to block target cell lysis (Table 10). From
these data it is apparent that Ts must suppress the induction of Tc after
sensitization, but before the generation of mature Tc. The target of
TsF in many antibody systems has been shown to be a helper T cell (Th)
(12). The action of TsF on Th does not prevent IL-2 production, or
associated cell proliferation, but does block production of antibody
(54). Although we have shown no direct proof of TsF, or Ts action on Th
the similarities in the systems suggests this mode of action.
In summary, we have shown that T cells derived from tumor-bearing
hosts enhance the growth of UV-induced progressor tumors in normal
animals, and are capable of abrogating tumor rejection in immune
syngeneic mice. The suppressor cell was characterized as labile in
vitro and sensitive to both cyclophosphamide and irradiation.
Studies on the specificity of the suppressor showed that it is directed
toward an antigen common to UV-induced progressor tumors but not present
on the MCA induced line 2331. The presence of a growing progressor tumor
does not result in an immunocompromised state allowing growth of
UV-induced regressor tumors, suggesting that suppression is directed to a
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TATA limited to progressor tumors. In vitro studies suggest that
the Ts may be capable of blocking proliferation of antigen specific Tc
but not NK cells.
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ABSTRACT
Murine UV-induced fibrosarcomas have been described as exceptional in
that they are highly antigenic, and most are rejected upon
transplantation into normal syngeneic hosts due to the production of
cytotoxic T lymphocytes directed toward the immunodominant tumor specific
transplantation antigen. A few of these tumors progress upon
transplantation to normal hosts; however, immunization with mitomycin C
treated progressor tumors results in immunity to challenge with the
immunizing tumor line. One rationale used to explain the continued
growth of a highly antigenic tumor is the presence of T suppressor cells.
Adoptive transfer of splenic T lymphocytes from C3H/HEN (MTV~) mice
bearing 14 day tumors to normal syngeneic mice, prior to tumor challenge,
resulted in enhanced rates of tumor growth. The suppressor cells were
characterized as being labile ±n vitro , sensitive to
cyclophosphamide and irradiation, and sensitive to treatment with
anti-I-J antibody and complement. Adoptive transfer of T cells from
tumor bearing animals to immune animals resulted in progressive tumor
growth. Specificity controls suggest that the T suppressor cell is
directed toward a tumor associated transplantation antigen common to
UV-induced fibrosarcomas, but not present on related methylcholanthrene
induced tumors.
Attempts to establish a reproducible assay of T suppressor function
in vitro were unsuccessful. Splenic T cells from tumor-bearing
hosts could not block lymphoproliferative response of lymphoid cells to
tumor antigen in mixed lymphocyte tumor cell cultures, and failed to
inhibit function of mature cytotoxic cells/measured in Chromium
release assay. Addition of exogenous interleukin-2 rich culture
supernatants to cultures of tumor-bearer spleen cells did not prevent
77
lability of T suppressor cells in vitro . Cytotoxicity resulting
from such cultures was nonspecific and capable of lysing the
methylcholanthrene induced tumor line 2331 . These results suggest that
suppressor cells may block the generation of antigen specific cytotoxic
cells but not lymphoproliferation and nonspecific immune responses.
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